I-Mab (IMAB) announced the pricing of an underwritten offering in the United States of 33,333,334 American Depositary Shares representing 76,666,668 ordinary shares at an offering price of $1.95 per ADS, for total gross proceeds of approximately $65M. All of the ADSs to be sold in the offering will be offered by I-Mab. The offering is expected to close on August 5, 2025, subject to customary closing conditions. The offering included participation from new and existing investors including Everest Medicines, Janus Henderson Investors, Adage Capital Partners LP and Exome Asset Management. Leerink Partners is acting as the lead bookrunning manager. BTIG is acting as a bookrunning manager. Lucid Capital Markets is acting as lead manager.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
- I-MAB Announces Preliminary Financial Results for Mid-2025
- I-Mab Acquires Bridge Health to Boost Givastomig Portfolio
- I-Mab entered into agreement to acquire 100% ownership of Bridge Health Biotech
- I-MAB Amends Prospectus for $21 Million ADS Offering
- I-MAB’s Givastomig Shows Promising Efficacy and Safety in Gastric Cancer, Earning Buy Rating